EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers

Fahima Hassanzada, Marion van Vugt, Mark Jansen, Annette F Baas, Anneline S J M Te Riele, Dennis Dooijes, Saskia N van der Crabben, Jan D H Jongbloed, Moniek G P J Cox, Ahmad S Amin, Ronald H Lekanne Deprez, Bram Ruijsink und 7 weitere

JACC: Advances · 2026-12 · 5 (12) · 103457

DOI: 10.1016/j.jacadv.2026.103457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Advances, 2026-12. Verfasst von Fahima Hassanzada und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; ERN-GUARD Heart, European Reference Network …. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR University College London Hospitals Biomedical Research Centre, DCVA, NWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in terms of onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. This study sought to identify protein biomarkers associated with HCM severity.

Methods

Olink-assayed plasma proteins of 144 MYBPC3 pathogenic variant carriers were tested for associations with HCM severity based on HCM diagnostic criteria (unaffected, mildly, or severely affected). The UK Biobank was used to replicate the identified proteins through considering time to onset of HCM (67 cases), cardiomyopathy (156 cases),and associations with cardiac MRI derived left ventricular maximum wall thickness (6,492 participants). Replicated proteins were further prioritised based on cardiac tissue expression and druggability, and annotated using pathway enrichment and association with onset of: heart failure (HF), dilated cardiomyopathy (DCM), sudden cardiac arrest (SCA), and ventricular arrhythmias (VA).

Results

Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity. We independently replicated 21 proteins in the UK Biobank. Of the five prioritised proteins (NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1), all but NT-proBNP were targeted by drugs with repurposing potential. The replicated proteins additionally associated with the incidence of HF (n=5), DCM (n=4), SCA (n=4), and VA (n=4).

Conclusion

This study replicated 21 and prioritised five proteins associated with HCM severity in pathogenic MYBPC3 variant carriers. Replication in unselected HCM suggests the prioritised proteins are associated with HCM independent of genotype, providing important leads for plasma-based markers for diagnoses, disease monitoring, and drug targets.

Schlagwörter

Stichwörter der Autor:innen

MYBPC3disease onset and progressiondrug target discoveryhypertrophic cardiomyopathyproteomics

Autor:innen und Institutionen

  • Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; ERN-GUARD Heart, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart, Amsterdam,…
  • Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Faculty of Population Health, Institute of Cardiovascular Science, University College Lo…
  • ERN-GUARD Heart, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart, Amsterdam, the Netherlands; Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Ut…
  • ERN-GUARD Heart, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart, Amsterdam, the Netherlands; Department of Human Genetics, Amsterdam University Medical Center, University of Amster…
  • Department of Genetics, University Medical Centre Groningen, Groningen, the Netherlands.
  • Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.

Förderung

  • NIHR University College London Hospitals Biomedical Research Centre
  • DCVA
  • NWO
  • Bristol Myers Squibb
  • ZonMw
  • British Heart Foundation
  • Amsterdam Cardiovascular Sciences
  • UK Research and Innovation

Zitieren

APA

Hassanzada, F., van Vugt, M., Jansen, M., Baas, A. F., Te Riele, A. S. J. M., Dooijes, D., van der Crabben, S. N., Jongbloed, J. D. H., Cox, M. G. P. J., Amin, A. S., Lekanne Deprez, R. H., Ruijsink, B., Kuster, D. W. D., van der Velden, J., Bezzina, C. R., Asselbergs, F. W., van Tintelen, J. P., van Spaendonck-Zwarts, K. Y., & Schmidt, A. F. (2026). Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers. JACC: Advances, 5(12), 103457. https://doi.org/10.1016/j.jacadv.2026.103457

Vancouver

Hassanzada F, van Vugt M, Jansen M, Baas AF, Te Riele ASJM, Dooijes D, et al. Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers. JACC: Advances. 2026;5(12):103457. doi:10.1016/j.jacadv.2026.103457

BibTeX
@article{Hassanzada2026,
  author = {Hassanzada, Fahima and van Vugt, Marion and Jansen, Mark and Baas, Annette F and Te Riele, Anneline S J M and Dooijes, Dennis and van der Crabben, Saskia N and Jongbloed, Jan D H and Cox, Moniek G P J and Amin, Ahmad S and Lekanne Deprez, Ronald H and Ruijsink, Bram and Kuster, Diederik W D and van der Velden, Jolanda and Bezzina, Connie R and Asselbergs, Folkert W and van Tintelen, J Peter and van Spaendonck-Zwarts, Karin Y and Schmidt, A Floriaan},
  title = {Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers},
  journal = {JACC: Advances},
  year = {2026},
  volume = {5},
  number = {12},
  pages = {103457},
  doi = {10.1016/j.jacadv.2026.103457}
}
Kostenlos starten →